TELA Bio reported a third-quarter 2026 adjusted (non-GAAP) net loss of $0.13 per share, beating the analyst consensus of roughly a $0.16 per share loss. Revenue of $18.96 million came in below the approximately $20 million consensus and declined about 8% year over year from $20.69 million.
The central target of about $5.20 is the rounded arithmetic mean of three current, verified analyst price targets, not a guarantee of future performance. The stock recently traded near $3.20 , meaning the target implies roughly 60% upside — a very large move.
Third-quarter 2026 revenue came in at $6.0 million , down 12.9% year over year and modestly below consensus estimates of about $6.2 million. Gross profit rose 21.2% to $3.3 million , reflecting improved margin performance even as top-line sales declined.
Lucid Diagnostics reported third-quarter 2026 revenue of $1.2 million, essentially flat versus $1.21 million a year earlier and below the roughly $1.63 million analyst consensus. The GAAP net loss narrowed to $6.7 million, or $0.03 per share, while the non-GAAP adjusted loss was about $10.6 million, or $0.06 per share — wider than the consensus loss of around $0.04 per share.
The central price target of $4.00 is the arithmetic mean of five current analyst price targets, which range from a low of $2.00 to a high of $9.50. With the stock trading near $0.38 , reaching $4.00 would require a gain of roughly 950% , an exceptionally large move.
The $12.50 central target is the arithmetic mean of three current analyst price targets — $10, $13, and $14 — rounded from a calculated average of roughly $12.33. With Owlet, Inc. (OWLT) trading near $4.60, reaching $12.50 would require a gain of about 172%, a very large move from current levels.
Fourth quarter 2025 revenue reached $26.6 million , up 29.6% year over year, capping a record full-year total of $105.7 million . Full-year 2025 gross margin hit a record 50.6% , even as tariff costs weighed on the fourth quarter margin of 47.6%.
Third-quarter 2026 revenue rose 86% year over year to $9.8 million, led by capital equipment sales of its TULSA-PRO platform. Net loss narrowed to $7.7 million, or $0.21 per share, compared with $8.0 million, or $0.26 per share, a year earlier — but came in slightly wider than the $0.19 consensus loss.
The central target examined here is $11 , the arithmetic mean of three verifiable current analyst price targets. The reviewed analyst targets span a tight range of $10 to $12 , with the stock trading near $7.44 at the time of writing.
The central $9.50 stock price target is the arithmetic mean of two verified, current analyst price targets ($9.00 and $10.00), matching the average reported by several aggregators. At a recent verified price near $6.73, reaching $9.50 would require a gain of roughly 41%, a substantial move.
CapsoVision reported third-quarter 2026 revenue of $3.568 million , up 0.8% from $3.538 million in the prior-year quarter. Net loss narrowed to $7.339 million , or $0.15 per share, compared with a loss of $7.921 million, or $0.17 per share, a year earlier.
The central target of $20 is the arithmetic mean of seven verified analyst price targets reviewed for NeuroPace, Inc. (NPCE) , ranging from $18 to $22. With shares recently trading near $12.50, reaching $20 would require a roughly 60% advance—a very large move.
NeuroPace reported third quarter 2026 revenue of $23.1 million , down 1.1% year over year and below the roughly $27.2 million consensus estimate. RNS (Responsive Neurostimulation) System revenue was $22.9 million , up just 1.4% from the prior-year quarter, reflecting softness concentrated in several large accounts.
Aethlon Medical, Inc. ( AEMD ) is a clinical-stage medical device company headquartered in San Diego, California, founded in 1984. Its lead product is the Hemopurifier , an investigational blood-filtration device designed to remove enveloped viruses and tumor-derived extracellular vesicles from circulation.
Regulatory inflection point: INBS submitted its 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) on September 9, 2026, seeking clearance of its fingerprint drug-screening system for codeine detection — the pivotal step toward its planned entry into the multi-billion-dollar U.S. drug-testing market. Recurring-revenue momentum: Cartridge consumables now drive the majority of sales, supported by a growing reader installed base of 1,978 units across 516 active customer accounts, positioning the company for higher-margin, repeatable demand.
Intelligent Bio Solutions Inc. ( INBS ) is a medical technology company that develops rapid, non-invasive drug screening and testing solutions. Its flagship product, the Intelligent Fingerprinting Drug Screening System , uses fingerprint sweat analysis to detect drugs of abuse in about ten minutes.
Regulatory inflection point: Adagio submitted a Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) in May 2026, positioning an agency decision as the single most important near-term catalyst for the stock forecast. Underpenetrated market opportunity: Sell-side research frames the company's addressable VT ablation market as large and underserved, with Piper Sandler describing a roughly $1.6 billion opportunity ahead of an anticipated 2027 U.S. launch.
Regulatory milestone ahead: The FDA's review of Beyond Air's second-generation LungFit PH system, including requested transport labeling, is the central catalyst that could expand the addressable market and position the company as a single-source nitric oxide provider. Accelerating commercial momentum: Management reaffirmed revenue guidance of $8 million for calendar 2026 and $16–$18 million for calendar 2027, implying more than 110% growth at the midpoint, contingent on second-generation approval.
XAIR is the Nasdaq ticker for Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company focused on nitric oxide (NO) therapies. The company's flagship product, LungFit PH, is a cylinder-free system that generates inhaled nitric oxide from ambient air, approved to treat persistent pulmonary hypertension of the newborn (PPHN).
Regulatory inflection point: Positive U.S. Food and Drug Administration (FDA) pre-submission feedback supporting a 510(k) clearance pathway (a streamlined Class II device-clearance route) for its standalone transvascular technology positions 2026–2027 as a pivotal window for regulatory progress. Intellectual property expansion: Recently granted U.S., Canadian, and European patents are deepening the company's protective moat around its catheter-based neural sensing platform ahead of potential commercialization.